ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0369

Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0345

Effectiveness and Safety of Apremilast in Biologic-Naive versus Biologic-Experienced Patients with Psoriatic Arthritis in Real-World Clinical Practice Settings in Germany: Interim Analysis of an Ongoing, Multicenter, Prospective, Non-interventional Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0107

Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation

Osteoporosis & Metabolic Bone Disease Poster

9:00AM-11:00AM: Abstract Number: 0208

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0217

Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0380

Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0352

Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0211

Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0375

Efficacy of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0363

Efficacy of Ixekizumab on Disease Activity and Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis and Objective Signs of Inflammation, Stratified by Baseline CRP/Sacroiliac Joint MRI Status

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0224

Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0381

Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0059

EHR-Supported Staff Protocol Improves Smoking Cessation in a Diverse Rheumatology Clinic: Results of Quit Connect Dissemination Project

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 0289

Endogenous Interferon-β and Low IL-4R on Transitional B Cells Promotes Lupus Nephritis

SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0428

Enrichment of Clinical Trial Recruitment Using Advanced Molecular Imaging in Takayasu’s Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

«Previous Page
1
…
8
9
10
11
12
…
35
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].